InterCure's wholly owned subsidiary, Canndoc, has entered into a strategic partnership agreement with Super-Pharm. Under the term of the agreement, Super-Pharm commits to acquiring 10 tons of Canndoc's GMP medical cannabis products during a three-year period. Canndoc's products will be securely transferred from its manufacturing facilities array to Super-Pharm’s distribution center, who will be responsible for the distribution to its 41 medical cannabis authorized pharmacies.
“We are looking to provide our patients with the best service and highest quality to meet the growing demands for medical cannabis products,” said Super-Pharm Chief Executive Officer Nitzan Lavi. “I welcome the strategic partnership with Canndoc which will enable us to increase our GMP standard medical cannabis inventory.”
Moshe Gavrilov, who recently joined the Board of Canndoc after 18 years in senior management positions at Teva Pharmaceutical industries, said, “This is a significant achievement which positions Canndoc as the leading company in the growing GMP standard medical cannabis.”
As part of the partnership, Canndoc will provide Super-Pharm and its pharmacists with professional and clinical expertise gained throughout its 12 years of development and treatment thousands of patients with medical cannabis. Canndoc will begin supplying its products to Super-Pharm immediately.
For more information:
Canndoc
#85 Medinat Hayehudim, Herzliya, Israel
+972 - 77 460 5012
[email protected]
canndoc-pharma.com